HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke
Vincaleukoblastin, 3-(Aminocarbonyl)-O-4-deacetyl-3-de(methoxycarbonyl)-, Sulfat (1:1) (Salz)
eldisine · Fildesi · Gesidine · Elsedine · LY-099094 · lilly99094 · vindesinasulfato · VINDESINE SULFATE
Identifikatoren & physikalische Daten
| CAS No. | 59917-39-4 |
|---|---|
| Summenformel | C43H57N5O11S |
| Durchschnittliche Molmasse | 852 g/mol |
| Monoisotopische Masse | 851,37752864 g/mol |
| SMILES | CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(N)=O)[C@H](O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O |
| InChIKey | COFJBSXICYYSKG-FJFFLIEUSA-N |
| PubChem CID | 43116 |
| ChEMBL | CHEMBL3989543 |
| ChEBI | CHEBI:32295 |
| EC No. | 261-984-7 |
| DTXSID | DTXSID0049074 |
| Lokaler Name | Vincaleukoblastin, 3-(Aminocarbonyl)-O-4-deacetyl-3-de(methoxycarbonyl)-, Sulfat (1:1) (Salz) |
Chemische & physikalische Eigenschaften
| Polarare Oberfläche (TPSA) | 248 |
|---|---|
| H-Brücken-Donoren | 7 |
| H-Brücken-Akzeptoren | 14 |
| Frei drehbare Bindungen | 7 |
| Schwere Atome | 60 |
| Formalladung | 0 |
| Komplexität | 1.650 |
| Schmelzpunkt | >2500C |
| Lagerbedingungen | 2-8°C |
| Löslichkeit | deionized water: ≥50mg/mL |
| Aggregatzustand | powder |
| Farbe | off-white to light yellow |
| Stabilität | Hygroscopic |
| InChIKey | COFJBSXICYYSKG-LBXFSOLBNA-N |
Sicherheit & Vorschriften
| GHS-Einstufung | DangerH300 (100%): Fatal if swallowed [Danger Acute toxicity, oral]P203, P264, P264+P265, P270, P280, P301+P316, P305+P354+P338, P317, P318, P321, P330, P405, and P501 (click each P-code to see the statement)The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory. |
|---|---|
| Hazard Classes and Categories | Acute Tox. 2 (100%) |
| Treatment | Activated charcoal binds most toxic agents and can decrease their systemic absorption if administered soon after ingestion. Immediate dilution with milk or water may be of benefit in caustic or irritant chemical ingestions. If the exposure occurred through inhalation, move patient to fresh air. Monitor for respiratory distress. If cough or difficulty breathing develops, evaluate for respiratory tract irritation, bronchitis, or pneumonitis. Administer oxygen and assist ventilation as required. Treat bronchospasm with inhaled beta2 agonist and oral or parenteral corticosteroids. in case of acute lung injury, Maintain ventilation and oxygenation and evaluate with frequent arterial blood gas or pulse oximetry monitoring. Following eye exposure, irrigate exposed eyes with copious amounts of room temperature water for at least 15 minutes. In case of dermal exposure, Remove contaminated clothing and wash exposed area thoroughly with soap and water. Treat dermal irritation or burns with standard topical therapy. Patients developing dermal hypersensitivity reactions may require treatment with systemic or topical corticosteroids or antihistamines. (T36) |
| Gesundheitliche Auswirkungen | The bone marrow depressant effects of vindesine may result in an increased incidence of microbial infection, delayed healing, and gingival bleeding (A609). |
| Expositionspfade | Ingestion, inhalation (T36, A566). |
| Toxizitätsübersicht | Vindesine acts by causing the arrest of cells in metaphase mitosis through its inhibition tubulin mitotic funcitoning. The drug is cell-cycle specific for the S phase. |
| Carcinogen Classification | No indication of carcinogenicity to humans (not listed by IARC). |
| Toxicity Data | LD50: 4 mg/kg (Mouse) |
| Wassergefährdungsklasse (WGK) | 3 |
Anwendungen & Verwendung
Verwenden
Vindesine Sulfate Salt is a synthetic derivative of the dimeric Catharanthus alkaloid vinblastine. Antineoplastic.